Wedbush Raises Benitec BioPharma (BNTC) Price Target to $20
Bullish analyst update, tempered by the uncertainty of a single price target and the company's biotech exposure.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst update, tempered by the uncertainty of a single price target and the company's biotech exposure.
What happened, with direct paths to the underlying reporting
Wedbush raised its price target on BNTC to $20; the posted price was $9.04. The update is bullish, though an analyst target is an opinion and does not establish likely performance.
Target: $20
Posted price: $9.04
Analyst firm: Wedbush
Analyst: Yun Zhong
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.